Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ACACB | O00763 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16375377 | 0.89 | MAPT (0.55) | MAPTTP53POLBTHRBKMT2A | |
| SCHEMBL14679174 | 0.88 | MAPT (0.66) | MAPTTP53POLBKMT2ATSHR | |
| SCHEMBL14757479 | 0.86 | MAPT (0.55) | MAPTTP53POLBTHRBKMT2A | |
| SCHEMBL4516428 | 0.83 | GPR119 (0.53) | MAPTTP53KMT2AMEN1ACACB | |
| SCHEMBL29471397 | 0.83 | MAPT (0.61) | MAPTTP53KMT2A | |
| SCHEMBL1106583 | 0.82 | MAPT (0.50) | MAPTTP53THRBKMT2AMEN1 | |
| SCHEMBL8279808 | 0.82 | MAPT (0.50) | MAPTTP53THRBKMT2AMEN1 | |
| SCHEMBL22637957 | 0.81 | KCNT1 (0.46) | MAPTPOLBKMT2ATSHR | |
| SCHEMBL14679175 | 0.79 | MAPT (0.58) | MAPTTP53KMT2AMEN1MAPK1 | |
| SCHEMBL14757470 | 0.79 | MAPT (0.52) | MAPTTP53POLBTHRBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150011508-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011508-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | KIT, PDGFRA, PDGFRB | MAPT 3899/4885TP53 388/4885POLB 2523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.